Ikapharmindo Putramas Tbk. (IKPM) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Ikapharmindo Putramas Tbk. IDR 181, price IDR 185, upside -2.2%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ikapharmindo Putramas Tbk. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
PT Ikapharmindo Putramas Tbk engages in the research and development, manufacturing, and marketing of pharmaceutical products in Indonesia. It operates through three segments: Non Pharma, Pharma, and Contract Manufacturing.
Show more
PT Ikapharmindo Putramas Tbk engages in the research and development, manufacturing, and marketing of pharmaceutical products in Indonesia. It operates through three segments: Non Pharma, Pharma, and Contract Manufacturing. The company offers prescription medicines in various areas, including neurology, psychiatry, dermatology, nephrology, gastroenterology, and nutraceuticals; and pharmaceuticals, vitamins, and over-the-counter products. It also provides hair and baby care products. PT Ikapharmindo Putramas Tbk was founded in 1978 and is headquartered in Jakarta Timur, Indonesia. PT Ikapharmindo Putramas Tbk is a subsidiary of PT Ikapharma Inti Mas.
Stock analysis
Ikapharmindo Putramas Tbk. (IKPM) currently trades at 185.00 IDR, while our model-based Fair Value estimate is 180.95 IDR, implying the stock looks roughly 2.2% fairly valued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 201.43 IDR per share, and 5 of the 7 models we run sit above the 185.00 IDR price.
Bear case: the Asset-Based group reads lowest at 86.99 IDR, and 2 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: 146.38 IDR (bear) to 240.58 IDR (bull), the price of 185.00 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Ikapharmindo Putramas Tbk. reported revenue of 364B IDR in FY2025 versus 399B IDR in FY2022, a compound −3.0%/yr. Reported net income was −28.8B IDR in FY2025.
Key figures
Market cap 312B IDR (≈ $17.4M) · P/S ratio 0.82 · Net margin −7.9% · Return on equity −11.4% · Return on assets (EBIT) 3.6% · Operating margin 3.1% · Revenue (TTM) 377B IDR · Revenue growth (YoY) +15.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −2%, IKPM screens richer than that median.
Fair Value models
Bear 146.38 IDRFair Value 180.95 IDRBull 240.58 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.6% (2022) → −6.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Ikapharmindo Putramas Tbk. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 61 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Ikapharmindo Putramas Tbk. (IKPM) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 180.95 IDR versus a price of 185.00 IDR, about −2% upside (fairly valued).
What is the fair value of IKPM?
Our model-based fair value for Ikapharmindo Putramas Tbk. is 180.95 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 185.00 IDR.
What is the quality score of IKPM?
Ikapharmindo Putramas Tbk. has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ikapharmindo Putramas Tbk. (IKPM)?
Our model-based price target is the fair value of 180.95 IDR (as of Sep 24, 2026) from 7 valuation models. Cautious scenario 146.38 IDR, optimistic scenario 240.58 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Ikapharmindo Putramas Tbk. stock forecast for 2026?
Our models put fair value at 180.95 IDR, about −2% upside versus a price of 185.00 IDR (fairly valued). Cautious scenario 146.38 IDR, optimistic scenario 240.58 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Ikapharmindo Putramas Tbk. (IKPM)?
Ikapharmindo Putramas Tbk. reported trailing-twelve-month revenue of about 377B IDR (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Ikapharmindo Putramas Tbk. (IKPM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ikapharmindo Putramas Tbk. it is 180.95 IDR per share (as of Sep 24, 2026), against a price of 185.00 IDR. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Ikapharmindo Putramas Tbk. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, IKPM trades above its calculated fair value: price 185.00 IDR, fair value 180.95 IDR, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IKPM?
No. The price is what the market pays today (185.00 IDR); the fair value is what the company's own numbers justify (180.95 IDR). For Ikapharmindo Putramas Tbk. the two are 4.05 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Ikapharmindo Putramas Tbk. worth?
The market values Ikapharmindo Putramas Tbk. at about 312B IDR (market capitalisation, as of Sep 24, 2026). Per share that is 185.00 IDR; our models calculate a fair value of 180.95 IDR per share.
What do the bullish and bearish scenarios say about IKPM?
Our models span a range for Ikapharmindo Putramas Tbk.: cautious scenario 146.38 IDR, base 180.95 IDR, optimistic 240.58 IDR per share (as of Sep 24, 2026, price 185.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ikapharmindo Putramas Tbk. (IKPM)?
Balance-sheet figures for Ikapharmindo Putramas Tbk. (as of Sep 24, 2026): return on equity −11.4%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is IKPM from its 52-week high?
Ikapharmindo Putramas Tbk. trades at 185.00 IDR, about 34% below its 52-week high of 282.00 IDR and 8% above the low of 171.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 180.95 IDR is for.
Which stocks are comparable to Ikapharmindo Putramas Tbk.?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ikapharmindo Putramas Tbk. stock attractive at the current price?
The data as of Sep 24, 2026: price 185.00 IDR, calculated fair value 180.95 IDR (−2%), Quality Score 47/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IKPM calculated?
We run Ikapharmindo Putramas Tbk. through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 180.95 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Ikapharmindo Putramas Tbk. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ikapharmindo Putramas Tbk. (IKPM)?
The closing price on Sep 24, 2026 was 185.00 IDR. Our model-based fair value is 180.95 IDR, about −2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ikapharmindo Putramas Tbk. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Ikapharmindo Putramas Tbk.
How large is the market capitalisation of Ikapharmindo Putramas Tbk. (IKPM)?
The market capitalisation of Ikapharmindo Putramas Tbk. is 312B IDR (≈ $17.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ikapharmindo Putramas Tbk. (IKPM)?
The price-to-sales ratio of Ikapharmindo Putramas Tbk. is 0.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Ikapharmindo Putramas Tbk. (IKPM)?
The net margin of Ikapharmindo Putramas Tbk. is −7.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ikapharmindo Putramas Tbk. (IKPM)?
The return on equity (ROE) of Ikapharmindo Putramas Tbk. is −11.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ikapharmindo Putramas Tbk. (IKPM)?
On an EBIT basis the return on assets of Ikapharmindo Putramas Tbk. is 3.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ikapharmindo Putramas Tbk. (IKPM)?
The operating margin of Ikapharmindo Putramas Tbk. is 3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ikapharmindo Putramas Tbk. (IKPM)?
Revenue at Ikapharmindo Putramas Tbk. is growing +15.0% versus a year earlier (3y avg −3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ikapharmindo Putramas Tbk. (IKPM)?
Earnings per share at Ikapharmindo Putramas Tbk. are growing −24.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Ikapharmindo Putramas Tbk. in the live analysis
One click puts Ikapharmindo Putramas Tbk. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
